Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Compass Therapeutics Inc (NASDAQ: CMPX) closed at $5.16 down -4.27% from its previous closing price of $5.39. In other words, the price has decreased by -$4.27 from its previous closing price. On the day, 1.18 million shares were traded. CMPX stock price reached its highest trading level at $5.43 during the session, while it also had its lowest trading level at $5.15.
Ratios:
For a deeper understanding of Compass Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.82 and its Current Ratio is at 17.82. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Citizens JMP on December 03, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On December 03, 2025, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $10.Canaccord Genuity initiated its Buy rating on December 03, 2025, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 917768384 and an Enterprise Value of 707740416.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.26, which has changed by 2.6174498 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $5.86, while it has fallen to a 52-week low of $1.33. The 50-Day Moving Average of the stock is 13.71%, while the 200-Day Moving Average is calculated to be 67.37%.
Shares Statistics:
For the past three months, CMPX has traded an average of 1.88M shares per day and 1747410 over the past ten days. A total of 177.57M shares are outstanding, with a floating share count of 124.31M. Insiders hold about 30.11% of the company’s shares, while institutions hold 61.21% stake in the company. Shares short for CMPX as of 1764288000 were 17414818 with a Short Ratio of 9.26, compared to 1761868800 on 16699205. Therefore, it implies a Short% of Shares Outstanding of 17414818 and a Short% of Float of 15.47.
Earnings Estimates
Investors are keenly observing as 11.0 analysts analyze and rate. The current performance of Compass Therapeutics Inc (CMPX) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.08 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.36 and -$0.5 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$0.42, with 11.0 analysts recommending between -$0.21 and -$0.6.
Revenue Estimates
Based on 13 analysts’ estimates, the company’s revenue will be $3.07M in the next fiscal year. The high estimate is $39.32M and the low estimate is -$36M.
